We are live on ! Find out more
LTRN icon

Lantern Pharma

33 hedge funds and large institutions have $13.1M invested in Lantern Pharma in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 3

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

32% more funds holding

Funds holding: 2533 (+8)

2.28% more ownership

Funds ownership: 12.53%14.81% (+2.3%)

16% less capital invested

Capital invested by funds: $15.7M → $13.1M (-$2.54M)

98% less call options, than puts

Call options by funds: $2K | Put options by funds: $122K

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
33
Holders Change
+8
Holders Change %
+32%
% of All Funds
0.51%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
13
Increased
12
Reduced
3
Closed
5
Calls
$2K
Puts
$122K
Net Calls
-$120K
Net Calls Change
-$120K

LTRN Hedge Fund Activity: Q4 2021 in Review

33 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q4 2021, worth a combined $13.1M — down 16% from $15.7M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new LTRN positions and 5 closed out — a net gain of 8 holders — while 12 added to existing stakes and 3 trimmed.

The largest buyer was Sanders Morris Harris, opening a new position worth an estimated $3.07M. The largest seller was Corriente Advisors, exiting entirely with an estimated $7M sold.

  • 33 institutional investors held Lantern Pharma (LTRN) as of Q4 2021, up from 25 in Q3 2021.
  • Funds reported $13.1M of Lantern Pharma stock for Q4 2021, down 16% quarter-over-quarter.
  • 13 funds opened new Lantern Pharma positions in Q4 2021 and 5 closed out, a net change of +8 holders.
  • The largest Lantern Pharma buyer in Q4 2021 was Sanders Morris Harris, an estimated $3.07M added.
  • The largest Lantern Pharma seller in Q4 2021 was Corriente Advisors, an estimated $7M sold.

Based on aggregated 13F filings for Q4 2021.